Germany-based Evotec has acquired of Kinaxo Biotechnologies, a drug discovery business with particular expertise in oncology. Completion of the deal gives Evotec access to technologies in drug discovery, efficacy, response predication, and safety assessment.

Evotec initially paid $17 million to acquire Kinaxo. Axel Ullrich, co-founder of Kinaxo, said: “The integration of [Kinaxo’s] leading drug discovery capability will implement Evotec as a driver towards personalized medicine in the future.”